IAXO-103 (CD14/TLR4 Antagonist) (synthetic) Cat. No. #IAX-600-003

Name: IAXO-103 (CD14/TLR4 Antagonist) (synthetic) Cat. No. #IAX-600-003 - 1 mg, UK VAT
Brand: Innaxon
Price: 222.00 GBP
Availability: InStock

The novel IAXO classes of glycolipid and benzylammonium lipids are synthetic TLR4/CD14 ligands with TLR4 modulating activities in vitro, and conferring protection against TLR4/CD14-mediated tissue damage and inflammation in vivo.

£185.00

Description Features Resources

Synonyms	N-(3,4-Bis-tetradecyloxy-benzyl)-N-cyclopentyl-N,N-dimethylammonium iodide. Small molecule CD14/TLR4 ligand/modulator. Benzylammonium lipid. Lipid A analogue.
Formula	C₄₂H₇₈INO₂
MW	755.98 g/mol (iodide salt)
CAS Number	1202208-36-3
Purity	≥98% according to TLC, NMR, MS analysis
Appearance	White solid

Solubility	Soluble in Methanol, DMSO and Ethanol 1:1 (vol:vol): >10mM
Handling	Reconstitution: For a 2mM stock solution, dissolve total vial content in 661µl (1mg size) in DMSO/Ethanol (1:1) (vol:vol).
Activity	Described to interfere with human, rat and mouse TLR4/CD14 signaling, other species not tested. Optimal working concentration depends upon the type, purity and concentration of TLR4 ligand, carrier protein such as LPS-binding protein (LBP), soluble and membrane-bound CD14, the presence of TLR4 co-receptors (e.g. CD36) as well on type and time of read-out (e.g. cytokine measurement in cell culture supernatant) or the biological outcome of in vivo experiments and therefore needs to be determined for each application. Recommended starting concentration: in vitro: 5µM, in vivo (rodent): 3mg/kg.

Download Product Resources

Product Data Sheet
Safety Data Sheet